{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:23:08Z","timestamp":1770967388190,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2002,11,1]]},"DOI":"10.1038\/sj.jhh.1001490","type":"journal-article","created":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T11:59:59Z","timestamp":1038311999000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The safety of valsartan: results of a postmarketing surveillance study on 12\u2009881 patients in England"],"prefix":"10.1038","volume":"16","author":[{"given":"P N","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L V","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S W","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,11,25]]},"reference":[{"key":"BF1001490_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2125.1993.tb04188.x","volume":"35","author":"MD Rawlins","year":"1993","unstructured":"Rawlins MD, Jefferys DB . United Kingdom product license applications involving new active substances, 1987\u20131989: their fate after appeals Br J Clin Pharmacol 1993 35: 599\u2013602","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 5","key":"BF1001490_CR2","first-page":"551","volume":"9","author":"LE Ramsay","year":"1995","unstructured":"Ramsay LE, Yeo WW . ACE inhibitors, angiotensin II antagonists and cough J Hum Hypertens 1995 9: (Suppl 5) 551\u2013554","journal-title":"J Hum Hypertens"},{"issue":"Suppl F","key":"BF1001490_CR3","first-page":"33F","volume":"11","author":"Y Lacourciere","year":"1995","unstructured":"Lacourciere Y, Lefebvre J . Modulation of the renin\u2013angiotensin\u2013aldosterone system and cough Can J Cardiol 1995 11: (Suppl F) 33F\u201339F","journal-title":"Can J Cardiol"},{"key":"BF1001490_CR4","unstructured":"Diovan Summary of Product Characteristics. Novartis 1996"},{"key":"BF1001490_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2125.1998.00774.x","volume":"46","author":"RD Mann","year":"1998","unstructured":"Mann RD . Prescription Event Monitoring\u2014recent progress and future horizons Br J Clin Pharmcol 1998 46: 195\u2013201","journal-title":"Br J Clin Pharmcol"},{"key":"BF1001490_CR6","unstructured":"WHO. International Ethical Guidelines for Biomedical Research Involving Human Subjects Geneva: CIOMS\/WHO 1993"},{"key":"BF1001490_CR7","unstructured":"Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. Royal College of Physicians of London August 1996"},{"key":"BF1001490_CR8","unstructured":"Multicentre Research Ethics Committee. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary Multi-Centre Research Ethics Committees Guidance Notes 2000 Appendix C: 19"},{"issue":"Suppl 1","key":"BF1001490_CR9","first-page":"1","volume":"6","author":"SN Freemantle","year":"1997","unstructured":"Freemantle SN et al. The incidence of the most commonly reported events with 40 newly marketed drugs\u2014study by Prescription-Event Monitoring Pharmacoepidemiol Drug Safety 1997 6: (Suppl 1) 1\u20138","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"BF1001490_CR10","first-page":"91","volume":"47","author":"L Templeton","year":"1997","unstructured":"Templeton L et al. Surveying general practitioners: does a low response rate matter? Br J Gen Pract 1997 47: 91\u201394","journal-title":"Br J Gen Pract"},{"key":"BF1001490_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"BR McAvoy","year":"1997","unstructured":"McAvoy BR, Kramer EFS . General practice postal surveys: a questionnaire too far? BMJ 1997 313: 732\u2013733","journal-title":"BMJ"},{"key":"BF1001490_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/sj.jhh.1000880","volume":"13","author":"RD Mann","year":"1999","unstructured":"Mann RD et al. Losartan: a study of pharmacovigilance data on 14\u2009522 patients J Hum Hypertens 1999 13: 551\u2013557","journal-title":"J Hum Hypertens"},{"key":"BF1001490_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00002018-199921010-00003","volume":"21","author":"L Mazzolai","year":"1999","unstructured":"Mazzolai L, Burnier M . Comparative safety and tolerability of Angiotensin II receptor antagonists Drug Safety 1999 21: 23\u201333","journal-title":"Drug Safety"},{"key":"BF1001490_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00003495-199754020-00009","volume":"54","author":"A Markham","year":"1997","unstructured":"Markham A, Goa KL . Valsartan: a review of its use in essential hypertension Drugs 1997 54: 299\u2013311","journal-title":"Drugs"},{"key":"BF1001490_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2125.1999.00855.x","volume":"47","author":"FJ Mackay","year":"1999","unstructured":"Mackay FJ, Pearce GL, Mann RD . Cough and angiotensin II inhibitors: cause or confounding? Br J Clin Pharmacol 1999 47: 111\u2013114","journal-title":"Br J Clin Pharmacol"},{"key":"BF1001490_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/j.1552-4604.1997.tb04767.x","volume":"37","author":"J Benz","year":"1997","unstructured":"Benz J et al. Valsartan, a new angiotensin II receptor antagonist: a double blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide J Clin Pharmacol 1997 37: 101\u2013107","journal-title":"J Clin Pharmacol"},{"key":"BF1001490_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israili","year":"1992","unstructured":"Israili ZH, Hall WD . Cough and angioneurotic oedema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology Ann Intern Med 1992 117: 234\u2013242","journal-title":"Ann Intern Med"},{"key":"BF1001490_CR18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"E Heeley","year":"2001","unstructured":"Heeley E et al. Prescription event monitoring and reporting of adverse drug reactions Lancet 2001 358: 1872\u20131873","journal-title":"Lancet"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001490","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:22:04Z","timestamp":1647537724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11,1]]}},"alternative-id":["BF1001490"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001490","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]},"assertion":[{"value":"29 May 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}